Literature DB >> 9655174

Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor.

I Kovalszky1, J Dudás, J Oláh-Nagy, G Pogány, J Töváry, J Timár, L Kopper, A Jeney, R V Iozzo.   

Abstract

Eukaryotic DNA topoisomerase I catalyzes changes in the superhelical state of duplex DNA by transiently breaking single strands thereby allowing relaxation of both positively and negatively supercoiled DNA. Topoisomerase I is a nuclear enzyme localized at active sites of transcription, and abnormal levels of the enzyme have been observed in a variety of neoplasms. Because the enzyme binds heparin and, given the presence of heparan sulfate within the nuclei of mammalian cells, we sought to investigate the interaction between topoisomerase I and sulfated glycosaminoglycans isolated from normal and neoplastic human liver. The results demonstrated that low concentrations (approximately 100 nM) of heparan sulfate from normal liver but not from its malignant counterpart effectively blocked relaxation of supercoiled DNA driven by either purified holoenzyme or topoisomerase I activity present in nuclear extracts of three malignant cell lines. Heparin acted at even lower (approximately 10 nM) concentrations. Moreover, we show that basic fibroblast growth factor could interfere with this heparan sulfate/heparin-driven inhibition and that both basic fibroblast growth factor and heparin-binding sites co-localized in the nuclei of U937 leukemic cells. Our results suggest that DNA topoisomerase I activity may be modulated in vivo by specific heparan sulfate moieties present in normal cells but markedly reduced or absent in their transformed counterparts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655174     DOI: 10.1023/a:1006898920637

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  72 in total

1.  Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.

Authors:  H Zhang; J C Wang; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Nuclear and cytoplasmic localization of different basic fibroblast growth factor species.

Authors:  M Renko; N Quarto; T Morimoto; D B Rifkin
Journal:  J Cell Physiol       Date:  1990-07       Impact factor: 6.384

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  A novel glycosaminoglycan-binding protein is the vertebrate homologue of the cell cycle control protein, Cdc37.

Authors:  N Grammatikakis; A Grammatikakis; M Yoneda; Q Yu; S D Banerjee; B P Toole
Journal:  J Biol Chem       Date:  1995-07-07       Impact factor: 5.157

5.  Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin.

Authors:  D S Gilmour; S C Elgin
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

6.  Altered glycosaminoglycan composition in reactive and neoplastic human liver.

Authors:  I Kovalszky; G Pogany; G Molnar; A Jeney; K Lapis; S Karacsonyi; A Szecseny; R V Iozzo
Journal:  Biochem Biophys Res Commun       Date:  1990-03-30       Impact factor: 3.575

7.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

8.  The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.

Authors:  J M Whitelock; A D Murdoch; R V Iozzo; P A Underwood
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

9.  Proteoglycan changes in the intercellular matrix of human colon carcinoma: an integrated biochemical and stereologic analysis.

Authors:  R V Iozzo; R P Bolender; T N Wight
Journal:  Lab Invest       Date:  1982-08       Impact factor: 5.662

10.  Inhibition of Moloney murine leukemia virus replication by tyrphostins, tyrosine kinase inhibitors.

Authors:  A Esther; S Iftach; P Esther
Journal:  FEBS Lett       Date:  1994-03-14       Impact factor: 4.124

View more
  27 in total

1.  Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.

Authors:  Anurag Purushothaman; Douglas R Hurst; Claudio Pisano; Shuji Mizumoto; Kazuyuki Sugahara; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

2.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

Review 3.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cis-acting elements: altered potential of hepatocellular carcinoma heparan sulphate.

Authors:  J Dudás; G Ramadori; T Knittel; K Neubauer; D Raddatz; K Egedy; I Kovalszky
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

5.  Prognostic value of heparanase expression and cellular localization in oral cancer.

Authors:  Yoav Leiser; Imad Abu-El-Naaj; Edmond Sabo; Sharon Akrish; Neta Ilan; Ofer Ben-Izhak; Micha Peled; Israel Vlodavsky
Journal:  Head Neck       Date:  2010-09-21       Impact factor: 3.147

6.  Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer.

Authors:  Lixin Zhang; Peggy Sullivan; Julie Suyama; Dario Marchetti
Journal:  Mol Cancer Res       Date:  2010-02       Impact factor: 5.852

7.  Inhibition of histone acetyltransferase by glycosaminoglycans.

Authors:  Jo Ann Buczek-Thomas; Edward Hsia; Celeste B Rich; Judith A Foster; Matthew A Nugent
Journal:  J Cell Biochem       Date:  2008-09-01       Impact factor: 4.429

Review 8.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

9.  Selective inhibition of bacterial and human topoisomerases by N-arylacyl O-sulfonated aminoglycoside derivatives.

Authors:  Amanda M Fenner; Lisa M Oppegard; Hiroshi Hiasa; Robert J Kerns
Journal:  ACS Med Chem Lett       Date:  2013-05-09       Impact factor: 4.345

Review 10.  Heparan sulfate in the nucleus and its control of cellular functions.

Authors:  Mark D Stewart; Ralph D Sanderson
Journal:  Matrix Biol       Date:  2013-12-03       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.